Compare CXH & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CXH | BYSI |
|---|---|---|
| Founded | 1989 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 58.4M |
| IPO Year | 1994 | 2016 |
| Metric | CXH | BYSI |
|---|---|---|
| Price | $7.94 | $1.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 102.5K | 9.2K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $36.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.34 | $1.21 |
| 52 Week High | $8.42 | $3.44 |
| Indicator | CXH | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 24.05 | 42.02 |
| Support Level | $7.89 | N/A |
| Resistance Level | $8.02 | $1.83 |
| Average True Range (ATR) | 0.08 | 0.16 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 17.31 | 31.40 |
Mfs Investment Grade Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowing for investment purposes, in tax-exempt bonds and tax-exempt notes.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.